WO2016073647A3 - COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS - Google Patents

COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS Download PDF

Info

Publication number
WO2016073647A3
WO2016073647A3 PCT/US2015/059104 US2015059104W WO2016073647A3 WO 2016073647 A3 WO2016073647 A3 WO 2016073647A3 US 2015059104 W US2015059104 W US 2015059104W WO 2016073647 A3 WO2016073647 A3 WO 2016073647A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
1alpha
over
expressing cancers
Prior art date
Application number
PCT/US2015/059104
Other languages
French (fr)
Other versions
WO2016073647A2 (en
Inventor
Wei Li
David Woodley
Mei Chen
Divya SAHU
Hangming DONG
Mengchen ZOU
Original Assignee
University Of Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Southern California filed Critical University Of Southern California
Priority to CN201580067543.8A priority Critical patent/CN107106669A/en
Priority to EP15856516.8A priority patent/EP3215186A4/en
Publication of WO2016073647A2 publication Critical patent/WO2016073647A2/en
Publication of WO2016073647A3 publication Critical patent/WO2016073647A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Described herein are compositions that include monoclonal antibodies that specifically bind Hsp90α and methods of using the same to treat HIF-1a-overexpressing cancer. In some embodiments, the cancers are breast cancer or lung cancer. The monoclonal antibodies bind the epitope TKPIWTRNP in Hsp90α or VKHFSVEGQ in Hsp90α
PCT/US2015/059104 2014-11-04 2015-11-04 COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS WO2016073647A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201580067543.8A CN107106669A (en) 2014-11-04 2015-11-04 Composition and method for treating the cancer for over-expressing the α of HIF 1
EP15856516.8A EP3215186A4 (en) 2014-11-04 2015-11-04 COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462075129P 2014-11-04 2014-11-04
US62/075,129 2014-11-04

Publications (2)

Publication Number Publication Date
WO2016073647A2 WO2016073647A2 (en) 2016-05-12
WO2016073647A3 true WO2016073647A3 (en) 2016-08-25

Family

ID=55910026

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/059104 WO2016073647A2 (en) 2014-11-04 2015-11-04 COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS

Country Status (3)

Country Link
EP (1) EP3215186A4 (en)
CN (1) CN107106669A (en)
WO (1) WO2016073647A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10273294B2 (en) 2010-10-11 2019-04-30 University Of Southern California Compositions and methods for treating HIF-1α over-expressing cancers
CN108337893B (en) * 2017-12-08 2019-11-26 深圳市人民医院 Slow virus carrier and the application of a kind of sgRNA and its building

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065734A1 (en) * 2007-11-16 2011-03-17 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
US20140199309A1 (en) * 2010-10-11 2014-07-17 University Of Southern California Fragment of secreted heat shock protein-90alpha (hsp90alpha) as vaccines or epitope for monoclonal antibody drugs or target for small molecule drugs against a range of solid human tumors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (en) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd Novel urokinase derivative, its preparation and thrombolytic agent containing the same
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US7342093B2 (en) * 2004-07-23 2008-03-11 University Of Massachusetts Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
CN102485720B (en) * 2009-10-30 2014-08-20 北京科美森医药研发有限公司 Heat shock protein 90 inhibitor
GB201004761D0 (en) * 2010-03-22 2010-05-05 Medical Res Council Method
JP2015525063A (en) * 2012-05-16 2015-09-03 シンタ ファーマスーティカルズ コーポレーション Pre-selection of subjects for treatment with HSP90 inhibitors based on hypoxia

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065734A1 (en) * 2007-11-16 2011-03-17 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
US20140199309A1 (en) * 2010-10-11 2014-07-17 University Of Southern California Fragment of secreted heat shock protein-90alpha (hsp90alpha) as vaccines or epitope for monoclonal antibody drugs or target for small molecule drugs against a range of solid human tumors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BHATIA ET AL.: "Secreted heat shock protein-90 alpha (Hsp90a) is essential for skin wound healing", 2015 ANNUAL MEETING OF THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY, J INVEST DERMATOL, vol. 135, 6 May 2015 (2015-05-06), pages S1 - S8, XP009502706 *
JAYAPRAKASH ET AL.: "Hsp90a and Hsp90b together operate a hypoxia and nutrient paucity stress-response mechanism during wound healing", JOURNAL OF CELL SCIENCE, vol. 128, no. 8, 3 March 2015 (2015-03-03), pages 1475 - 1480, XP055439613 *
LI ET AL.: "Dual Lysine Motif in Linker Region of Heat Shock Protein-90alpha Defines Tumorigenicity of its Secreted Form in Breast Cancer Cells", VLLTH INTERNATIONAL SYMPOSIUM ON HEAT SHOCK PROTEINS IN BIOLOGY & MEDICINE, 2 November 2014 (2014-11-02), XP009502698 *

Also Published As

Publication number Publication date
CN107106669A (en) 2017-08-29
WO2016073647A2 (en) 2016-05-12
EP3215186A4 (en) 2018-10-24
EP3215186A2 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
MX2020012797A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
JOP20190291A1 (en) Antibody molecules to cd73 and uses thereof
NZ738008A (en) Tigit-binding agents and uses thereof
SA517381703B1 (en) Anti-C10orf54 Antibodies And Uses Thereof
PH12019501393A1 (en) Afucosylated anti-fgfr2iiib antibodies
EA201892294A1 (en) ANTIBODIES AND COMPOSITIONS AGAINST TIM-3
MX2018009700A (en) Bcma antibodies and use of same to treat cancer and immunological disorders.
MX2017004311A (en) Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof.
MX2017004715A (en) Humanized anti-ox40 antibodies and uses thereof.
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
EA201691824A1 (en) ANTIBODIES AGAINST EGFRVIII AND THEIR APPLICATIONS
MX2018008934A (en) Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same.
PH12017500890A1 (en) Antibody drug conjugates
MX2016012124A (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof.
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
MX2018010295A (en) Antibodies having specificity for btla and uses thereof.
JOP20200312A1 (en) Factor xi antibodies and methods of use
WO2016055432A3 (en) Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents
IL260935A (en) Methods for treating er , her2-, hrg breast cancer using combination therapies comprising an anti-erbb3 antibody
WO2018031490A3 (en) Anti-ox40 binding proteins
WO2017136659A3 (en) Humanized anti-cd3 antibodies, conjugates and uses thereof
EP3645040A4 (en) Use of anti-fam19a5 antibodies for treating cancers
WO2015054600A3 (en) Glycan-interacting compounds and methods of use

Legal Events

Date Code Title Description
REEP Request for entry into the european phase

Ref document number: 2015856516

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015856516

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15856516

Country of ref document: EP

Kind code of ref document: A2